inPROBE®

Smart Cancer Diagnostics

INPROBE

We create the Future of Fighting Cancer and give oncologists technology to increase patients survival rate.

One core platform technology: wide scale-up opportunities and applications.

One vision: Increase Cancer Cure Rate by min. 30% by 2030.

European Funds Smart Growth
Polska
European Union European Regional Development Fund

DISRUPTIVE PLATFORM TECHNOLOGY WITH GLOBAL POTENTIAL TO CHALLENGE THE PARADIGM OF TARGETED BIOLOGY DIAGNOSTICS AND REAL-TIME TARGETED DRUGS DELIVERY MONITORING

Nowadays millions of people die each year from cancer. It's a medical professionals to save lives of patients worldwide. At the same time the future of cancer therapies is here, several targeted or gene therapies are gaining trust, but their efficiency strictly depends on proper and real-time targeted tumor biology diagnostics, which does not exist today. That's why we've invented and developed **INPROBE**, a platform technology which links targeted therapies with targeted diagnostics. Our technology will reduce diagnosis time, will increase precision and effects of innovative cancer treatments. It can be used both in cancer diagnostics and therapies monitoring, in real time and in natural state, thus giving medical professionals a fast and efficient tools previously unavailable.

PERSONALIZED TARGETED POINT-OF-CARE DIAGNOSTICS

HELPING ONCOLOGISTS TO IDENTIFY THE RIGHT PATIENTS WHO BENEFIT THE MOST FROM INNOVATIVE TARGETED TREATMENTS

PATIENTS WELLBEING

Less pain. No waiting time. Immediate personalized targeted treatment introduction lowering high stress

IN VIVO EXAMINATION AND REAL TIME RESULTS

No tissue biopsy
Results in minutes

HIGH SENSITIVITY

No tumor infraction benefiting with no CANCER METASTASIS. Enough to get close to the tumor with USG guidance

NUMEROUS SCALE-UP POSSIBILITIES

FUTURE

Most cancer biomarkers
Real-time drug delivery in SITU monitoring
Surgical oncology
Infectious diseases
and many others

OBJECTIVE RESULTS

Numerical results
No more false results

OUR VISION

Increase cancer cure rate by min. 30% by 2030

Our vision is to develop innovative cancer diagnostics & monitoring technologies which will help increase cancer survival by 30% by 2030. We will achieve that with implementing real-time, in vivo (closest possible to disease condition) and numerical based technologies.

8,2 mln

people will die this year because of cancer

70%

the increase in new cases of cancer expected over the next 2 decades

Breast Cancer

2 million new cases of Breast Cancer in 2018

0.5 million deaths

Real-Time in vivo, no false +/- targeted tumor biology diagnostics is KEY

Standard Biopsy

results in days
visual examination
often false +/- results

InPROBE

results in minutes
numerical results
no false results

DISRUPTIVE TECHNOLOGY WITH WIDE SCALE-UP OPPORTUNITIES

HOW IT WORKS?



- Disruptive 6-micron opto-biological Platform Technology
- Merging fiber optics, biotech and engineering in a single needle
- In essence putting the biology diagnostics tests at the tip of the fiber optic Microprobe
- Single-cell resolution Microprobe HER2 tumor biomarker in breast cancers as first in-human clinical application (Phase 2 of clinical trials running)
- Shorten tumor markers testing from several days or weeks to several minutes, without painful tissue biopsy and laboratory waiting-time

HELPING ONCOLOGISTS TO IDENTIFY THE RIGHT PATIENTS WHO BENEFIT THE MOST FROM INNOVATIVE TARGETED TREATMENTS

INPROBE CAN INCREASE CANCER CURE BY 30% BY 2030

www.inprobe.com

HOW IT WORKS?



TESTIMONIALS

SDS-MicroProbe can be a groundbreaking solution to overcome problems in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am con- vinced that such solution would find several applications in rsearch as well as in future cell therapies in the cancer area.

Hematologist/Oncologist M.D. PhD
with several years of scientific experience at NIH
Bethesda, MD, USA

There is an unmet need to study biological processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyzing key intracellular parameters that indicate the functionality of a cell. The SDS- MicroProbe has the potential to substantially advance our ability to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficacy of interventions.

Prof. PhD of Harvard Medical School
Boston, MA, USA

The InProbe has the potential to swiftly replace traditional IHC and FISH examinations, should this be confirmed by correlation studies of the probe results and quantitative analysis of HER2 expression. Further applications will appear very soon, together with newly introduced targeted drugs in clinical practice. There are several dozens of them today.

Prof. PhD. D.D.
European Society of Surgical Oncology (ESSO)
Board Member
Lublin, Poland

www.inprobe.com

ABOUT US

At SDS Optic we strive to make a difference in the world. We connect vast medical knowledge with technical skills to create technologies that can revolutionize global healthcare.

Our team consists of renown experts in biology, optoelectronics, medicine, advanced technologies, chemistry, biomedical engineering and related sciences.

SDS OPTIC
Lifesaving Innovations

SDS Optic strategy is to discover, develop, produce and commercialize our unique diagnostics and monitoring tools on a global scale. We want to develop life saving innovations which can help medical professionals in real-time.

Our team concentrate on assisting healthcare with faster, less painful diagnostics and supporting targeted, effective treatment procedures.

OUR VISION IS TO INCREASE CANCER CURE BY 30% BY 2030

2013

First trials of inPROBE on animal living cells

SDS Optic develops 6-micron diameter optical fibre tip: the base technology of inPROBE

2014

First presentations of the **inPROBE** technology in the USA and Europe, receives positive testimonials

2015

The National Center of Research and Development (NCBiR) grants €2,6M to cover all R&D expenses

2016

First round of laboratory tests – the device is successfully tested in vitro in search of tumor markers

2017

SDS Optic applies for 2 independent patents in PCT worldwide procedure

Pre-clinical testing on mouse models

SME Instrument Horizon2020 grants €4M funding to run clinical trials and implement commercialisation strategy

GLOBAL PRESENCE

2018

R&D Centre kick-off in Lublin. Team of Biology, Chemist, Physics & Engineering Ph.Ds and M.Sc.

INNOventure VC fund €750K Series A investment

3 new patent applications in PCT Worldwide procedure

2019

Final stage of preclinical trials on rat models with human HER2 overexpressing breast cancer cell lines derived from living cancer patients

SDS Optic Ltd. becoming **SDS Optic Inc.** - a first setp towards becoming a public company

First technology scale-up opportunities In-vitro studies

Clinical Trials Phase1 kick-off

2020

Clinical Trials Phase2 - interventional studies with almost 200 patients in 5 cancer centres in Central Europe

Technology scale-up - building -re-clinical phase projects pipeline

Pre-IPO Series B fundraising

M&A Strategy - technologies focused on Lifesaving Innovations

2021

Clinical Trials Completion

CE Mark and ISO13485 Cetrification

Initial Public Offering (IPO) and long term enterprise value building for Shareholders

Wide Core Technology applications - new tumor cancer, endoscopy app, therapies monitoring, surgical oncology

2022

FDA & EMA Approvals

Market Go Live

Global organization

OUR TEAM



Magdalena Staniszewska, PhD, DSc.
Co-Founder / Chief Science Officer

Leading biotechnology scientist with several years of experience at Harvard Medical School in Boston, MA (USA) and the Polish Academy of Sciences. A scientist with broad experience in discovering molecular bases of diseases, identifying targets and developing new therapeutic strategies for diabetic complications, cancer and eye diseases. Co-invented analytical tools and diagnostic markers of pathological neovessels, holds a track record of scientific publications and public speaking.

Przemysław Kopyto, M.D.
Chief Medical Officer

Lublin Medical University M.D. and Harvard Business School graduate. Oncology pharmaceutical market expert, many years spent with leading pharmaceuticals as Head of Immunology and Oncology business teams. Ran several clinical trials and marketed several oncology medicines.

Marcin Staniszewski, MSc Eng.
Co-Founder, CEO & Senior Engineer

Experienced scientist and engineer with several years of experience in R&D engineering projects obtained at US companies, incl. NASA Laboratory and Glenn Research Center in Cleveland, OH. University of Akron (Akron, OH) graduate, founder of several technology startups in the United States.

Mateusz Sagan, MBA
Chief Business Officer / Member of the Supervisory Board

Experienced Leader and Executive Manager, specialized in strategic management, sales management, biotech/medtech start-ups commercialization and business development. Several years as CEO and Board Executive at large international corporate businesses in the U.S., Switzerland and Eastern Europe, in BPO and consumer goods sectors. TEDx Speaker, MBA graduate from University of Central Lancashire Preston, UK

We are cooperating with breast cancer foundations:

Rak 'n' Roll

AVON BREAST CANCER CRUSADE

www.inprobe.com

SDS OPTIC IN MEDIA

You can find information about us on our social media channels, in breaking news, tv programs and press realeases.

facebook.com/OncoMicroprobe
instagram.com/sdsoptic
twitter.com/OncoMicroprobe
youtube.com SDS Optic
linkedin.com SDS Optic
inprobe.com

European Funds Smart Growth
Polska
European Union
European Regional Development Fund

inPROBE®
Smart Cancer Diagnostics

www.inprobe.com

SDS OPTIC
Lifesaving Innovations

SDS Optic Inc.
Konstantynow 1F
20708 Lublin
Poland

Tel +48 81 501 94 63
email: office@sdsoptic.pl
www.sdsoptic.pl